WO2000057918A2 - Novel formulations comprising lipid-regulating agents - Google Patents
Novel formulations comprising lipid-regulating agents Download PDFInfo
- Publication number
- WO2000057918A2 WO2000057918A2 PCT/US2000/007459 US0007459W WO0057918A2 WO 2000057918 A2 WO2000057918 A2 WO 2000057918A2 US 0007459 W US0007459 W US 0007459W WO 0057918 A2 WO0057918 A2 WO 0057918A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- polyoxyethylene
- caprylic
- oil
- lipid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002367995A CA2367995A1 (en) | 1999-03-31 | 2000-03-21 | Novel formulations comprising lipid-regulating agents |
MXPA01009839A MXPA01009839A (en) | 1999-03-31 | 2000-03-21 | Novel formulations comprising lipid-regulating agents. |
JP2000607667A JP2002540174A (en) | 1999-03-31 | 2000-03-21 | Novel formulation containing lipid regulator |
AU40175/00A AU4017500A (en) | 1999-03-31 | 2000-03-21 | Novel formulations comprising lipid-regulating agents |
EP00919496A EP1165141A2 (en) | 1999-03-31 | 2000-03-21 | Novel formulations comprising lipid-regulating agents |
HK02104718.1A HK1044704A1 (en) | 1999-03-31 | 2002-06-25 | Novel formulations comprising lipid-regulating agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28335699A | 1999-03-31 | 1999-03-31 | |
US09/283,356 | 1999-03-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000057918A2 true WO2000057918A2 (en) | 2000-10-05 |
WO2000057918A3 WO2000057918A3 (en) | 2001-01-18 |
Family
ID=23085656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/007459 WO2000057918A2 (en) | 1999-03-31 | 2000-03-21 | Novel formulations comprising lipid-regulating agents |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1165141A2 (en) |
JP (1) | JP2002540174A (en) |
AU (1) | AU4017500A (en) |
CA (1) | CA2367995A1 (en) |
HK (1) | HK1044704A1 (en) |
MX (1) | MXPA01009839A (en) |
WO (1) | WO2000057918A2 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002100394A1 (en) * | 2001-06-12 | 2002-12-19 | Galephar M/F | Oral pharmaceutical composition containing a statin derivative |
JP2003342171A (en) * | 2002-05-23 | 2003-12-03 | Usv Ltd | Composition for administering dithranol |
WO2005034920A1 (en) * | 2003-10-10 | 2005-04-21 | Lifecycle Pharma A/S | A solid dosage form comprising a fibrate |
US6982281B1 (en) | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
WO2006045865A1 (en) | 2004-10-19 | 2006-05-04 | Gp Pharm S.A. | Pharmaceutical formulation comprising microcapusles of statins suspended in alkyl esters of polyunsaturated fatty acids (pufa) |
US7927627B2 (en) | 2002-05-24 | 2011-04-19 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US7976869B2 (en) | 2001-01-22 | 2011-07-12 | Laboratoires Fournier S.A. | Fenofibrate tablets |
EP2400840A1 (en) * | 2009-02-24 | 2012-01-04 | Madeira Therapeutics | Liquid statin formulations |
WO2012171364A1 (en) * | 2011-06-13 | 2012-12-20 | 浙江爱生药业有限公司 | Oil-soluble pharmaceutical composition |
US9173847B2 (en) | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
WO2015185240A1 (en) | 2014-06-04 | 2015-12-10 | Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. | Compositions containing simvastatin in omega-3 polyunsaturated fatty acids |
US9757389B2 (en) | 2014-08-28 | 2017-09-12 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US9757390B2 (en) | 2010-11-30 | 2017-09-12 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10561615B2 (en) | 2010-12-10 | 2020-02-18 | Lipocine Inc. | Testosterone undecanoate compositions |
US11052096B2 (en) | 2009-01-08 | 2021-07-06 | Lipocine Inc. | Steroidal compositions |
US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
US11707467B2 (en) | 2014-08-28 | 2023-07-25 | Lipocine Inc. | (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006062933A2 (en) * | 2004-12-06 | 2006-06-15 | Reliant Pharmaceuticals, Inc. | Stable compositions of fenofibrate with fatty acid esters |
JP5186159B2 (en) * | 2006-08-31 | 2013-04-17 | あすか製薬株式会社 | Fenofibrate-containing composition |
JP2013047282A (en) * | 2006-08-31 | 2013-03-07 | Aska Pharmaceutical Co Ltd | Fenofibrate-containing composition |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0336298A1 (en) * | 1988-03-31 | 1989-10-11 | E.R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
WO1995024893A1 (en) * | 1994-03-16 | 1995-09-21 | R.P. Scherer Limited | Delivery systems for hydrophobic drugs |
WO1999012528A1 (en) * | 1997-09-11 | 1999-03-18 | Smb Technology | Self-emulsifiable semi-solid capsules with matrix system having prolonged action |
WO1999029300A1 (en) * | 1997-12-10 | 1999-06-17 | Rtp Pharma Inc. | Self-emulsifying fenofibrate formulations |
-
2000
- 2000-03-21 EP EP00919496A patent/EP1165141A2/en not_active Withdrawn
- 2000-03-21 MX MXPA01009839A patent/MXPA01009839A/en unknown
- 2000-03-21 CA CA002367995A patent/CA2367995A1/en not_active Abandoned
- 2000-03-21 WO PCT/US2000/007459 patent/WO2000057918A2/en not_active Application Discontinuation
- 2000-03-21 JP JP2000607667A patent/JP2002540174A/en not_active Withdrawn
- 2000-03-21 AU AU40175/00A patent/AU4017500A/en not_active Abandoned
-
2002
- 2002-06-25 HK HK02104718.1A patent/HK1044704A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0336298A1 (en) * | 1988-03-31 | 1989-10-11 | E.R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
WO1995024893A1 (en) * | 1994-03-16 | 1995-09-21 | R.P. Scherer Limited | Delivery systems for hydrophobic drugs |
WO1999012528A1 (en) * | 1997-09-11 | 1999-03-18 | Smb Technology | Self-emulsifiable semi-solid capsules with matrix system having prolonged action |
WO1999029300A1 (en) * | 1997-12-10 | 1999-06-17 | Rtp Pharma Inc. | Self-emulsifying fenofibrate formulations |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6982281B1 (en) | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US7976869B2 (en) | 2001-01-22 | 2011-07-12 | Laboratoires Fournier S.A. | Fenofibrate tablets |
WO2002100394A1 (en) * | 2001-06-12 | 2002-12-19 | Galephar M/F | Oral pharmaceutical composition containing a statin derivative |
JP2003342171A (en) * | 2002-05-23 | 2003-12-03 | Usv Ltd | Composition for administering dithranol |
US7927627B2 (en) | 2002-05-24 | 2011-04-19 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US7931917B2 (en) | 2002-05-24 | 2011-04-26 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US9173847B2 (en) | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
US8481078B2 (en) | 2003-10-10 | 2013-07-09 | Veloxis Pharmaceuticals A/S | Solid dosage form comprising a fibrate |
US7658944B2 (en) | 2003-10-10 | 2010-02-09 | Lifecycle Pharma A/S | Solid dosage form comprising a fibrate |
US8124125B2 (en) | 2003-10-10 | 2012-02-28 | Veloxis Pharmaceuticals A/S | Solid dosage form comprising a fibrate |
WO2005034920A1 (en) * | 2003-10-10 | 2005-04-21 | Lifecycle Pharma A/S | A solid dosage form comprising a fibrate |
WO2006045865A1 (en) | 2004-10-19 | 2006-05-04 | Gp Pharm S.A. | Pharmaceutical formulation comprising microcapusles of statins suspended in alkyl esters of polyunsaturated fatty acids (pufa) |
US11052096B2 (en) | 2009-01-08 | 2021-07-06 | Lipocine Inc. | Steroidal compositions |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
EP2400840A1 (en) * | 2009-02-24 | 2012-01-04 | Madeira Therapeutics | Liquid statin formulations |
EP2400840A4 (en) * | 2009-02-24 | 2012-08-01 | Madeira Therapeutics | Liquid statin formulations |
US9757390B2 (en) | 2010-11-30 | 2017-09-12 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10799513B2 (en) | 2010-11-30 | 2020-10-13 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9943527B2 (en) | 2010-11-30 | 2018-04-17 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9949985B2 (en) | 2010-11-30 | 2018-04-24 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10226473B2 (en) | 2010-11-30 | 2019-03-12 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10973833B2 (en) | 2010-11-30 | 2021-04-13 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10716794B2 (en) | 2010-11-30 | 2020-07-21 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10561615B2 (en) | 2010-12-10 | 2020-02-18 | Lipocine Inc. | Testosterone undecanoate compositions |
WO2012171364A1 (en) * | 2011-06-13 | 2012-12-20 | 浙江爱生药业有限公司 | Oil-soluble pharmaceutical composition |
WO2015185240A1 (en) | 2014-06-04 | 2015-12-10 | Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. | Compositions containing simvastatin in omega-3 polyunsaturated fatty acids |
US9757389B2 (en) | 2014-08-28 | 2017-09-12 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US11298365B2 (en) | 2014-08-28 | 2022-04-12 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US11707467B2 (en) | 2014-08-28 | 2023-07-25 | Lipocine Inc. | (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use |
US11872235B1 (en) | 2014-08-28 | 2024-01-16 | Lipocine Inc. | Bioavailable solid state (17-β)-Hydroxy-4-Androsten-3-one esters |
US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
Also Published As
Publication number | Publication date |
---|---|
HK1044704A1 (en) | 2002-11-01 |
AU4017500A (en) | 2000-10-16 |
JP2002540174A (en) | 2002-11-26 |
EP1165141A2 (en) | 2002-01-02 |
MXPA01009839A (en) | 2002-06-21 |
CA2367995A1 (en) | 2000-10-05 |
WO2000057918A3 (en) | 2001-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6372251B2 (en) | Formulations comprising lipid-regulating agents | |
EP1165141A2 (en) | Novel formulations comprising lipid-regulating agents | |
EP1162954A1 (en) | Novel formulations comprising lipid-regulating agents | |
US6465011B2 (en) | Formulations comprising lipid-regulating agents | |
EP1140036A2 (en) | Novel formulations comprising lipid-regulating agents | |
RU2211047C2 (en) | Gelatin capsule with solid film including oil-free pharmaceutically compositions | |
US20040052824A1 (en) | Micellar colloidal pharmaceutical composition containing a lipophilic active principle | |
US6838091B2 (en) | Formulations comprising lipid-regulating agents | |
US6719999B2 (en) | Formulations comprising lipid-regulating agents | |
WO1999029300A1 (en) | Self-emulsifying fenofibrate formulations | |
RU2249461C2 (en) | Cyclosporin-containing and practically oil-free compositions | |
NZ552390A (en) | Novel fenofibrate formulations and related methods of treatment | |
US6814977B1 (en) | Formulations comprising lipid-regulating agents | |
US20020040046A1 (en) | Novel formulations comprising lipid-regulating agents | |
SK7342000A3 (en) | Formulations comprising dissolved paroxetine | |
US7014864B1 (en) | Formulations comprising lipid-regulating agents | |
EP1183017A1 (en) | Novel formulations comprising lipid-regulating agents | |
EP2034957A2 (en) | Pharmaceutical composition for oral administration | |
MXPA06005247A (en) | Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative | |
MXPA99006916A (en) | Oil-free pharmaceutical compositions containing cyclosporin a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2367995 Country of ref document: CA Ref country code: CA Ref document number: 2367995 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 607667 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/009839 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000919496 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000919496 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000919496 Country of ref document: EP |